IMRX vs. CCCC, FHTX, BNTC, URGN, ATAI, LFCR, HRTX, DSGN, ELDN, and CMPS
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include C4 Therapeutics (CCCC), Foghorn Therapeutics (FHTX), Benitec Biopharma (BNTC), UroGen Pharma (URGN), Atai Life Sciences (ATAI), Lifecore Biomedical (LFCR), Heron Therapeutics (HRTX), Design Therapeutics (DSGN), Eledon Pharmaceuticals (ELDN), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry.
Immuneering vs.
Immuneering (NASDAQ:IMRX) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
Immuneering has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Immuneering's return on equity.
Immuneering has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the S&P 500.
Immuneering currently has a consensus target price of $12.80, indicating a potential upside of 533.66%. C4 Therapeutics has a consensus target price of $10.67, indicating a potential upside of 170.73%. Given Immuneering's higher possible upside, analysts clearly believe Immuneering is more favorable than C4 Therapeutics.
Immuneering received 5 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Immuneering an outperform vote while only 39.13% of users gave C4 Therapeutics an outperform vote.
67.7% of Immuneering shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 25.0% of Immuneering shares are held by insiders. Comparatively, 8.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Immuneering has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immuneering had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Immuneering and 4 mentions for C4 Therapeutics. Immuneering's average media sentiment score of 0.64 beat C4 Therapeutics' score of 0.03 indicating that Immuneering is being referred to more favorably in the media.
Summary
Immuneering beats C4 Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
This page (NASDAQ:IMRX) was last updated on 1/21/2025 by MarketBeat.com Staff
